Mary E Palumbo, FNP-C | |
9500 Euclid Ave, Cleveland, OH 44195-0001 | |
(216) 444-2200 | |
Not Available |
Full Name | Mary E Palumbo |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 9500 Euclid Ave, Cleveland, Ohio |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194291682 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | F07182393 (Ohio) | Secondary |
363LF0000X | Nurse Practitioner - Family | F07182393 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mary E Palumbo, FNP-C 245 Warwick Ct, Aurora, OH 44202-8543 Ph: (330) 502-0663 | Mary E Palumbo, FNP-C 9500 Euclid Ave, Cleveland, OH 44195-0001 Ph: (216) 444-2200 |
News Archive
A potentially life-saving treatment for sepsis has been under our noses for decades in the non-steroidal anti-inflammatory drugs most people have in their medicine cabinets, a new University of Colorado Boulder study suggests.
Scientists know that a better understanding of how proteins bond could lead to more effective treatments for genetic disorders and other life-threatening conditions.
Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink EliteĀ® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).
For patients with IgA nephropathy, a type of kidney disease, steroid treatment can prevent or delay loss of kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). IgA nephropathy is an autoimmune disease that affects the kidneys and a major cause of end-stage kidney failure in younger people
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.
› Verified 5 days ago